Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Auspex Pharmaceuticals

2001 FOUNDED
M&A STATUS
31-40 EMPLOYEES
M&A LATEST DEAL TYPE
$3.5B LATEST DEAL AMOUNT
Description

Developer of deuterated analogs of clinically-validated drugs. The company develops a pipeline of therapeutics that improves on existing drugs across various therapeutic areas. It focuses on the development of drugs for the treatment of involuntary movement disorders, respiratory disease and inflammation.

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Parent Company
Teva Pharmaceutical Industries
Primary Office
  • 3366 North Torrey Pines Court
  • Suite 225
  • San Diego, CA 92037
  • United States

+1 (858) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Auspex Pharmaceuticals’s full profile, request a free trial.

Auspex Pharmaceuticals Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
16. Merger/Acquisition 05-May-2015 $3.5B 00000 00.00 Completed Clinical Trials - Phase 3
15. 2PO 30-Jan-2015 00000 00000 Completed Clinical Trials - Phase 3
14. 2PO 11-Jul-2014 000.00 00000 00000 Completed Clinical Trials - Phase 3
13. IPO 05-Feb-2014 0000 00000 00000 Completed Clinical Trials - Phase 3
12. Loan 08-Jan-2014 0000 00000 Completed Clinical Trials - Phase 3
11. Later Stage VC (Series E) 20-Dec-2013 000.00 00000 00000 Completed Clinical Trials - Phase 3
10. Later Stage VC (Series D) 06-Sep-2013 0000 0000 000.00 Completed Clinical Trials - Phase 3
9. Loan 11-Mar-2013 0000 Completed Clinical Trials - Phase 3
8. Later Stage VC 09-Nov-2012 $19M $70M Completed Clinical Trials - Phase 3
7. Later Stage VC 28-Dec-2011 $3M $51M Completed Generating Revenue
To view this company’s complete deal history including valuation and funding, request access »

Auspex Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series E 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series D 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.00
Series C 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series B 0,000,000 00.000000 00 00.0 00.0 00 00.0 0.000
Series A5 00,000 00.000000 00 00.0 00.0 00 00.0 0.000
Series A4 000,000 00.000000 00 00.0 00.0 00 00.0 0.000
Series A3 000,000 00.000000 00 00.0 00.0 00 00.0 0.000
Series A2 610,294 $0.000100 8% $1.7 $1.7 1x $1.7 0.87%
Series A1 613,500 $0.000100 8% $1 $1 1x $1 0.88%
To view this company’s complete Cap Table, request access »

Auspex Pharmaceuticals Former Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
BioMed Ventures Corporate Venture Capital Minority 000 0000 000000 0
Costa Verde Capital Venture Capital Minority 000 0000 000000 0
Deerfield Management Venture Capital Minority 000 0000 000000 0
Foresite Capital Management Growth/Expansion Minority 000 0000 000000 0
Panorama Capital Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 8 investors. Get the full list »

Auspex Pharmaceuticals Executive Team (11)

Name Title Board
Seat
Contact
Info
Pratik Shah Ph.D President, Chief Executive Officer & Board Member
Andreas Sommer Ph.D Chief Scientific Officer

9 Former Executives

You’re viewing 2 of 11 executives. Get the full list »

Auspex Pharmaceuticals Board Members (7)

Name Representing Role Since Contact
Info
Gerald Proehl Self Board Member 000 0000

6 Former Board Members

You’re viewing 1 of 7 board members. Get the full list »